Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1142446

	registered interest
	date	25/07/2019
	answering body	Leader of the House of Lords
	answering dept id	92
	answering dept short name
	answering dept sort name	Leader of the House of Lords
	hansard heading	House of Lords: Times of Sittings
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask the Leader of the House, in the light of the impact of climate change on air quality, transport and health, and forecasts of higher temperatures in future years, what plans she has to review whether the House should sit in July.
	tabling member printed	Lord Jones of Cheltenham
	uin	HL17520
	answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>The Government schedules business in the House and proposes dates for Recess with the agreement of the usual channels. The House needs to sit for as long as there is business to be completed. The Government has no plans to review whether the House should sit in July in future years.</p> answering member printed Baroness Evans of Bowes Park question first answered 26/07/2019 12:49:51 answering member 4329 label Biography information for Baroness Evans of Bowes Park
	tabling member	248 label Biography information for Lord Jones of Cheltenham

1141957

	registered interest
	date	24/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Breast Cancer: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what are the drugs approved by NICE to treat HER2+ breast cancer; and what assessment they have made of the efficacy of such drugs.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL17501
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for making recommendations for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources.</p><p>NICE has recommended the following drugs for the treatment of HER2-positive breast cancer: trastuzumab emtansine (Kadcyla) for treating HER2-positive advanced breast cancer after trastuzumab (Herceptin) and a taxane; pertuzumab (Perjeta) with trastuzumab (Herceptin) and docetaxel for treating HER2-positive breast cancer; pertuzumab (Perjeta) for the neoadjuvant treatment of HER2-positive breast cancer; and pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer.</p><p>NHS commissioners are legally required to fund drugs recommended in NICE technology appraisal guidance. It is for clinicians to decide on the most appropriate treatment for an individual patient based on their clinical judgement and in discussion with the patient.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL17502 question first answered 25/07/2019 16:45:03 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

1141958

	registered interest
	date	24/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pertuzumab
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what advice they provide to clinicians for the use of Pertuzumab rather than Herceptin for the treatment of HER2+ breast cancer.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL17502
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for making recommendations for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources.</p><p>NICE has recommended the following drugs for the treatment of HER2-positive breast cancer: trastuzumab emtansine (Kadcyla) for treating HER2-positive advanced breast cancer after trastuzumab (Herceptin) and a taxane; pertuzumab (Perjeta) with trastuzumab (Herceptin) and docetaxel for treating HER2-positive breast cancer; pertuzumab (Perjeta) for the neoadjuvant treatment of HER2-positive breast cancer; and pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer.</p><p>NHS commissioners are legally required to fund drugs recommended in NICE technology appraisal guidance. It is for clinicians to decide on the most appropriate treatment for an individual patient based on their clinical judgement and in discussion with the patient.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL17501 question first answered 25/07/2019 16:45:03 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

1141255

	registered interest
	date	23/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Non-surgical Cosmetic Procedures: Children
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what legal duties govern the administering of dermal fillers to people under the age of 18 by non-regulated practitioners.
	tabling member constituency	North Durham
	tabling member printed	Mr Kevan Jones
	uin	280927
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Currently there are no restrictions that limit the administration of dermal fillers on young people under the age of 18 years old.</p><p>The Department is exploring options to introduce age restrictions on access to cosmetic procedures, bringing them in line with legislation on tattoos, teeth whitening and the use of sunbeds. From May 2020 all dermal fillers, irrespective of their composition and intended use, will be regulated as medical devices under Annex XVI of the Medical Device Regulations (EU 2017/745). The new Regulations will significantly improve the quality and safety of dermal fillers.</p><p>The Government is committed to improving the safety of cosmetic procedures through better training for practitioners, and clear information so that people can make informed decisions about their care. The growth in non-surgical treatments increases the need for consumer protection and we are currently working with stakeholders to strengthen the regulation of cosmetic procedures.</p><p>We urge anyone seeking a cosmetic procedure to take the time to find a reputable, insured and appropriately qualified practitioner who is either subject to statutory regulation or on a voluntary register accredited by the Professional Standards Authority.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 25/07/2019 16:32:36 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	1438 label Biography information for Mr Kevan Jones

1141380

	registered interest
	date	23/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	MMR Vaccine: Safety
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to maintain and improve pharmacovigilance in relation to the MMR vaccine.
	tabling member constituency	Gravesham
	tabling member printed	Adam Holloway
	uin	280998
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>As with all vaccines and medicines, the safety of the Measles, Mumps and Rubella (MMR) vaccine remains under continual review by the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA uses all available sources of evidence in pharmacovigilance, including regular review of suspected adverse reactions submitted through the Yellow Card Scheme, data from clinical and epidemiological studies, the medical literature and information from pharmaceutical companies and other worldwide regulatory authorities. The MHRA’s processes and data analysis systems are regularly evaluated to ensure optimal performance in monitoring the safety of vaccines and medicines.</p><p>The balance of benefits and risks of MMR vaccine remains overwhelmingly favourable.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 25/07/2019 16:35:38 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	1522 label Biography information for Adam Holloway

1141381

	registered interest
	date	23/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	MMR Vaccine
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure (a) transparency and (b) accountability in the process of manufacturing the MMR vaccine.
	tabling member constituency	Gravesham
	tabling member printed	Adam Holloway
	uin	280999
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Two Measles, Mumps and Rubella (MMR) vaccines are licensed for use in the United Kingdom: M-M-RVaxPro and Priorix. Both vaccines are on the National Health Service’s routine immunisation schedule. The quality, safety and efficacy of both M-M-RVaxPro and Priorix have been evaluated before they were given a Marketing Authorisation in Europe, and the Marketing Authorisation Holder for each vaccines is legally required to submit periodic safety update reports to the regulator, which are documents intended to provide an evaluation of the risk-benefit balance of a medicinal product at defined time points after its authorisation. The sites at which the products are manufactured are also required to undergo periodic inspections to ensure that they comply with Good Manufacturing Practices. Each batch of vaccines is tested by an official medicines control laboratory (OMCL). OMCL testing is independent of and in addition to the manufacturer’s testing. These procedures ensure that the MMR vaccines available in the UK are safe and efficacious and that the manufacturers/Marketing Authorisation holders are held accountable for their products.</p><p>A European Public Assessment Report (EPAR) for M-M-RVaxPro is available at the following link:</p><p><a href="https://www.ema.europa.eu/en/documents/scientific-discussion/m-m-rvaxpro-epar-scientific-discussion_en.pdf" target="_blank">https://www.ema.europa.eu/en/documents/scientific-discussion/m-m-rvaxpro-epar-scientific-discussion_en.pdf</a></p><p>Priorix was approved before public assessment reports were a requirement. The EPAR for M-M-RVaxPro contains a general summary of the manufacturing information that was provided during the assessment process; however, the specific details of the manufacturing process are confidential.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 25/07/2019 16:38:57 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	1522 label Biography information for Adam Holloway

1141399

	registered interest
	date	23/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Speech and Language Therapy: Children and Young People
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the report of the Children's Commissioner entitled, We need to talk: Access to speech and language therapy, published in June 2019, what plans he has to ensure that expenditure data is collected on the support local areas provide for children and young people with speech, language and communication needs.
	tabling member constituency	Birmingham, Edgbaston
	tabling member printed	Preet Kaur Gill
	uin	281095
	answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>The Department is keen to work with the Children’s Commissioner’s Office and other partners on options for producing expenditure data on speech, language and communication services. Officials will discuss this matter at the next available opportunity.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 26/07/2019 11:45:16 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4603 label Biography information for Preet Kaur Gill

1141473

	registered interest
	date	23/07/2019
	answering body	Treasury
	answering dept id	14
	answering dept short name	Treasury
	answering dept sort name	Treasury
	hansard heading	Wills: VAT
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Chancellor of the Exchequer, what assessment he has made of the potential merits of removing VAT from wills that include a charitable donation.
	tabling member constituency	Newcastle-under-Lyme
	tabling member printed	Paul Farrelly
	uin	280957
	answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>Under current EU law, it is not possible to remove VAT on fees for writing wills where those wills include charitable donations.</p> answering member constituency Hereford and South Herefordshire answering member printed Jesse Norman question first answered 26/07/2019 10:19:44 answering member 3991 label Biography information for Jesse Norman
	tabling member	1436 label Biography information for Paul Farrelly

1140791

	registered interest
	date	22/07/2019
	answering body	Department for Work and Pensions
	answering dept id	29
	answering dept short name	Work and Pensions
	answering dept sort name	Work and Pensions
	hansard heading	Universal Credit: Mental Illness
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Work and Pensions, pursuant to the Answer of 17 May 2019 on Universal Credit: Mental Illness, whether her Department provides support visits for benefit claimants in secure psychiatric settings.
	tabling member constituency	Bristol West
	tabling member printed	Thangam Debbonaire
	uin	280236
	answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>The Department is committed to supporting vulnerable claimants, such as those with mental health conditions. We understand that these claimants may face extra challenges in their lives. Universal Credit is designed to target resources at those that need them most and to provide support for people who cannot work or need extra help moving towards the labour market.</p><p>If a claimant is unable to complete their business transaction through any other channel, a referral for a visit is sent to DWP Visiting. The majority of DWP Visiting work takes place in claimants’ homes, however appointments can be arranged at an alternative place such as a hospital or low secure unit.</p><p>We recognise the importance of understanding how a mental health condition impacts someone’s ability to prepare for and look for work. That is why we have developed a range of specialised mental health training for work coaches and increased the number of Disability Employment Advisers who can provide additional support where needed.</p><p><strong> </strong></p><p>The Department is committed to the provision of a safe and healthy working environment for employees and claimants, therefore all our visits, irrespective of location, are individually risk assessed which determines the most appropriate means of engagement.</p> answering member constituency North Swindon answering member printed Justin Tomlinson question first answered 26/07/2019 10:25:13 answering member 4105 label Biography information for Justin Tomlinson
	tabling member	4433 label Biography information for Thangam Debbonaire

1140794

	registered interest
	date	22/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medicine: Research
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of UK capacity in translational research.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	280239
	answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>The Medical Research Council (MRC) covers basic through to translational research, with translational research and applied, clinical, public health and social care research funded by the Department via the National Institute for Health Research (NIHR).</p><p>The NIHR’s funding for research includes support for research infrastructure which is critically important in providing the resources, support and facilities that the National Health Service needs to conduct first-class research across the full pathway of discovery science to evaluation. The sustained, long-term funding to put in place through the NIHR infrastructure has been widely recognised as having transformed the health research environment in the United Kingdom. For example, there has been five-fold increase in early phase (phase I and phase II) trials since 2009 within the NIHR early translational research infrastructure in the NHS (2,842 phase I and phase II trials in 2017/18 compared to just 496 in 2009/10).</p><p>The MRC are also currently undertaking an evaluation of 10 years of MRC-funded translation research which is expected to be completed in September 2019.</p><p>The MRC and the NIHR also work in partnership through the Efficacy and Mechanism Evaluation programme which funds studies evaluating interventions with potential to make a step-change in the promotion of health, treatment of disease and improvement of rehabilitation or long-term care.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 26/07/2019 11:44:44 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4131 label Biography information for Jim Shannon